REDUCE LAP-HF TRIAL II

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 608 participants.

Also called NCT03088033

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 608 participants (planned count) (from the registry)
Sponsor
Corvia Medical (from the registry)
Registry
  • NCT NCT03088033
Other papers using this trial's data
  • 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II JACC. Heart failure, 2024-08 DOI, PubMed 38934964
  • Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction JACC. Heart failure, 2023-10 DOI, PubMed 37480877
  • Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial JAMA cardiology, 2024-06-01 DOI, PubMed 38630494, PMC11024798 Not in the PMC Open Access subset.
  • Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction JACC. Heart failure, 2023-08 DOI, PubMed 36939661, PMC11185159 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Expanded Definition of Worsening Heart Failure: Impact on Clinical Outcomes and Quality-of-Life Assessment JACC. Heart failure, 2025-09 DOI, PubMed 40714684
  • Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II JACC. Heart failure, 2026-10 DOI, PubMed 42268170

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, Croatia, Denmark, France, Germany, Italy, Japan, Netherlands, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03088033. Randomized; triple masking; primary purpose treatment. Start 2017-06-01 (actual); primary completion 2021-07-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REDUCE LAP-HF TRIAL II
Condition
Heart Failure
Intervention (Device)
IASD System II implant
Intervention (Other)
intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Lead sponsor
Corvia Medical (class: industry)

Record details

Record id
cardio:ct-nct03088033
Content hash
cd3b30a16f60f60287246a8f02888a93cd39995b97ea7799333330cc80d7c8cf